



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tolycaine

Cat. No.:	HY-105584
CAS No.:	3686-58-6
Molecular Formula:	C ₁₅ H ₂₂ N ₂ O ₃
Molecular Weight:	278.35
Target:	Others
Pathway:	Others
Storage:	Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (359.26 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.5926 mL	17.9630 mL	35.9260 mL
	5 mM		0.7185 mL	3.5926 mL	7.1852 mL
	10 mM		0.3593 mL	1.7963 mL	3.5926 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.58 mg/mL (9.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.58 mg/mL (9.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.58 mg/mL (9.27 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Tolycaine is a local anaesthetic. Tolycaine also induces a convulsive response in experimental animals^[1].

In Vivo

Tolycaine (140, 150 mg/kg; i.p.; single) induces convulsions by modification of monoamines in rat brain^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (190-230 g) ^[1] .
Dosage:	130, 140, 150, 165 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Produced clonic convulsions following ataxia and the loss of the righting reflex and the frequency of convulsions was dose-dependently intensified, as shown by shortening of the latency and prolongations of the duration and the sedation time. Produced a significant elevation of noradrenaline and 5-hydroxytryptamine levels in all brain regions in the convulsive state from the levels in the non-convulsive state when at 140 mg/kg. Led to rats took the opisthotonic position, gasped for breath, and died during the convulsions when dosage more than 150 mg/kg.

REFERENCES

[1]. Satoh T, et al. Pharmacological analysis of local anaesthetic tolucaine-induced convulsions by modification of monoamines in rat brain. *Pharmacol Toxicol.* 1996 Dec;79(6):305-11.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA